Search

Displaying results 6591 - 6600 of 7554 in total
  1. Drug

    Bermekimab

    go.drugbank.com/drugs/DB14947
    Investigational

    Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).

  2. Drug

    Clopenthixol

    go.drugbank.com/drugs/DB13841
    Investigational

    Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

  3. Drug

    Endothelin-1

    go.drugbank.com/drugs/DB12652
    Investigational

    Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).

  4. Drug

    RST-001

    go.drugbank.com/drugs/DB17843
    Investigational

    RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.

  5. Drug

    Felzartamab

    go.drugbank.com/drugs/DB16375
    Investigational

    Felzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).

  6. Drug

    Eltrekibart

    go.drugbank.com/drugs/DB19017
    Investigational

    Eltrekibart is under investigation in clinical trial NCT06046729 (A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa).

  7. Drug

    Lilotomab

    go.drugbank.com/drugs/DB19076
    Investigational

    Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).

  8. Drug

    Batoclimab

    go.drugbank.com/drugs/DB16104
    Investigational

    Batoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).

  9. Drug

    SynKIR-110

    go.drugbank.com/drugs/DB17365
    Investigational

    SynKIR-110 are autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR).

  10. Drug

    PRX-ASL

    go.drugbank.com/drugs/DB17679
    Experimental

    PRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.